| Device |
sensor, glucose, invasive, component of automated insulin delivery system |
| Definition |
The device is intended to measure glucose in interstitial fluid. It is intended to provide those measurements as inputs to appropriately qualified digitally connected devices, including automated insulin dosing systems, as determined by FDA. |
| Physical State |
This device comprises a glucose specific biological sensor, an algorithm that converts sensor signals into glucose values, and a mechanism for transmitting data from the sensor to specific connected devices. |
| Technical Method |
Signals from a glucose specific biological sensor are algorithmically converted to glucose values which are transmitted to specific connected devices. |
| Target Area |
Diagnostics |
| Review Panel |
Clinical Chemistry |
| Product Code | SFI |
| Premarket Review |
Office of In Vitro Diagnostics
(OHT7)
Division of Chemistry and Toxicology Devices
(DCTD)
|
| Submission Type |
PMA
|
| Device Class |
3
|
| Total Product Life Cycle (TPLC) |
TPLC Product Code Report
|
| GMP Exempt? |
No
|
Summary Malfunction Reporting |
Ineligible |
| Implanted Device? |
No
|
| Life-Sustain/Support Device? |
No
|
| Third Party Review |
Not Third Party Eligible |